Johnson & Johnson dividend profile
Johnson & Johnson is presented here as an income-research page that combines yield, payout discipline, dividend growth, and company-specific watch items.
Johnson & Johnson is usually studied as a steadier U.S. dividend profile because healthcare demand, product breadth, and a long payout culture make it a classic income research name.
Income investors often use JNJ as a benchmark for what a lower-yield, steadier dividend profile can look like when business quality matters as much as payout size.
Yield reflects the price and distribution information represented by the dated source snapshot. It can change as the market price or declared distribution changes.
Dividend yield, payout ratio, yield on cost, and dividend safety.
Data provenance
Yield and payout were rechecked on August 26, 2026. The August 25 ex-dividend date has passed; the declared Q3 dividend remains scheduled for payment on September 8, 2026.
- Research dataset: S&P Global Market Intelligence via StockAnalysis; five-year growth via Investing.com
- Company / primary source: Johnson & Johnson Q3 2026 dividend announcement
Metrics observed 2026-08-26. Site-wide stock data review completed 2026-08-26.
Research checklist
- Litigation and product-liability overhang
- Healthcare portfolio reshaping and capital allocation
- Whether dividend growth remains comfortably covered by underlying cash generation
A strong income case usually needs more than one green flag. The useful combination is payout room, business durability, valuation context, and a believable path to future cash generation.
Dividend history data status
This page intentionally shows the audited metric set and avoids publishing a year-by-year payout series until the company-level history table is fully validated against the stock dataset.
The repository no longer publishes synthetic annual payout histories. A complete series will be added only after company-specific historical distributions, corporate actions, and currency treatment are validated.
See Data Sources and Methodology for how site-wide figures should be interpreted. Company filings, exchange announcements, and official investor-relations materials remain authoritative for current dividend decisions.